Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog: Interspecies relationship comparing with human pharmacokinetics

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 2, 2001, Pages 134-144

  Pahlman I ^a   Kankaanranta, S ^a   Palmer L ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

CAS 124937 51 5; Muscarinic receptor antagonist; Tolterodine, disposition, dog, mouse, pharmacokinetics, rat

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ANIMAL EXPERIMENT; ARTICLE; BLADDER IRRITATION; CORRELATION FUNCTION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; NONHUMAN; RAT;

EID: 0035116809     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300015     Document Type: Article

References (28)

1. Current concepts in the treatment of disorders of micturition
2. The overactive bladder: Pharmacologic basis of drug treatment
3. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo
4. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability
5. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
6. Tolterodine - A new bladder-selective antimuscarinic agent
7. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data
8. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
9. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
10. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
11. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes
12. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine
13. Influence of CYP 2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
14. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity
15. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mouse, rat and dog
16. Efficient biliary excretion of susalimod, probably via the bromosulphtalein carrier, studied in a chronic bile fistula model in dogs
17. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry
18. Serum protein binding of tolterodine and its major metabolites in humans and several animal species
19. Interspecies scaling, allometry, physiological time and ground plan of pharmacokinetics
20. In-vitro and in-situ determination of the intestinal absorption of tolterodine, a new muscarinic receptor antagonist
21. Comparison between permeability coefficients in rat and human jejunum
22. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols
23. Man versus beast: Pharmacokinetic scaling in mammals
24. Interspecies scaling and comparisons in drug development and toxicokinetics
25. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins
26. Interspecies pharmacokinetics of a novel hemoregulatory peptide (SK&F 107647) in rats, dogs and oncological patients
27. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor
28. Prediction of the distribution of beta-lactam antibiotics in humans from pharmacokinetic parameters in humans